Tuesday, July 10, 2007

Bayer's blood-clot drug beats Lovenox in key study

From the Scotsman (UK):
Bayer AG's experimental pill rivaroxaban is significantly more effective than standard injections of Lovenox in preventing blood clots after knee surgery, researchers said on Sunday.

The news confirms the German drugmaker's leadership in the multibillion-dollar race to bring a new class of oral anticoagulants to market.

Results of a large Phase III trial showed only 9.6 percent of patients given rivaroxaban experienced venous thromboembolism (VTE), or blood clots, following total knee replacement against 18.9 percent of those on Sanofi-Aventis SA's Lovenox. ...more

No comments: